Literature DB >> 21677377

Potentiation of tau aggregation by cdk5 and GSK3β.

Sangmook Lee1, Garth F Hall, Thomas B Shea.   

Abstract

Hyperphosphorylation of tau is closely associated with its aggregation by as yet undefined mechanisms. We attempted herein to further investigate the interrelationships between tau aggregation and phosphorylation by inhibition and activation of cdk5 and GSK3β in cells expressing normal tau and a mutant form of tau (3PO-tau), which generates intracellular aggregates while retaining microtubule-binding capacity). Aggregates were routinely observed in cells expressing 3PO-tau, but never in cells expressing normal tau, whether or not cdk5 or GSK3β was overexpressed. In addition, in cells expressing 3PO-tau, both the percentage of cells with aggregates, as well as the size of aggregates, was increased following overexpression of cdk5 or GSK3β, decreased following treatment with pharmacological agents (roscovitine and lithium) active against these kinases, and increased following treatment with the phosphatase inhibitor okadaic acid. These findings collectively indicate that phosphorylation potentiates aggregation in the presence of one or more key tau mutations. These findings confirm and extend prior studies in which overexpression of the cdk5 activator p35, or GSK3β, induced phosphorylation, mislocalization and/or aggregation of tau.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21677377     DOI: 10.3233/JAD-2011-102016

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  9 in total

1.  Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screening.

Authors:  Arindam Chatterjee; Stephen J Cutler; Robert J Doerksen; Ikhlas A Khan; John S Williamson
Journal:  Bioorg Med Chem       Date:  2014-09-28       Impact factor: 3.641

Review 2.  Cell cycle proteins in brain in mild cognitive impairment: insights into progression to Alzheimer disease.

Authors:  Jeriel T R Keeney; Aaron M Swomley; Jessica L Harris; Ada Fiorini; Mihail I Mitov; Marzia Perluigi; Rukhsana Sultana; D Allan Butterfield
Journal:  Neurotox Res       Date:  2011-11-15       Impact factor: 3.911

3.  Cyclin-Dependent kinase 5 targeting prevents β-Amyloid aggregation involving glycogen synthase kinase 3β and phosphatases.

Authors:  John Fredy Castro-Alvarez; Alejandro Uribe-Arias; Gloria Patricia Cardona-Gómez
Journal:  J Neurosci Res       Date:  2015-02-24       Impact factor: 4.164

Review 4.  Hyperphosphorylated tau is implicated in acquired epilepsy and neuropsychiatric comorbidities.

Authors:  Ping Zheng; Sandy R Shultz; Chris M Hovens; Dennis Velakoulis; Nigel C Jones; Terence J O'Brien
Journal:  Mol Neurobiol       Date:  2013-12-10       Impact factor: 5.590

Review 5.  The Role of Cdk5 in Alzheimer's Disease.

Authors:  Shu-Lei Liu; Chong Wang; Teng Jiang; Lan Tan; Ang Xing; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2015-07-31       Impact factor: 5.590

6.  Effects of Thioflavin T and GSK-3 Inhibition on Lifespan and Motility in a Caenorhabditis elegans Model of Tauopathy.

Authors:  Andrea Gamir-Morralla; Sandra Sacristán; Miguel Medina; Teresa Iglesias
Journal:  J Alzheimers Dis Rep       Date:  2019-02-16

7.  Caspase-mediated truncation of tau potentiates aggregation.

Authors:  Sangmook Lee; Thomas B Shea
Journal:  Int J Alzheimers Dis       Date:  2012-09-04

Review 8.  Biochemical Markers in Alzheimer's Disease.

Authors:  Alessandro Rabbito; Maciej Dulewicz; Agnieszka Kulczyńska-Przybik; Barbara Mroczko
Journal:  Int J Mol Sci       Date:  2020-03-14       Impact factor: 5.923

Review 9.  Interaction between Aβ and Tau in the Pathogenesis of Alzheimer's Disease.

Authors:  Huiqin Zhang; Wei Wei; Ming Zhao; Lina Ma; Xuefan Jiang; Hui Pei; Yu Cao; Hao Li
Journal:  Int J Biol Sci       Date:  2021-05-27       Impact factor: 6.580

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.